A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

BACKGROUND: Pelareorep is an oncolytic virus with activity in many cancers including prostate. It has in vitro synergism with microtubule-targeted agents. We undertook a clinical trial evaluating pelareorep in mCRPC patients receiving docetaxel. PATIENTS AND METHODS: In this randomized, open-label p...

Descripción completa

Detalles Bibliográficos
Autores principales: Eigl, Bernhard Josef, Chi, Kim, Tu, Dongsheng, Hotte, Sebastien J., Winquist, Eric, Booth, Christopher M., Canil, Christina, Potvin, Kylea, Gregg, Richard, North, Scott, Zulfiqar, Muhammad, Ellard, Susan, Ruether, Joseph Dean, Le, Lyly, Kakumanu, A. Saranya, Salim, Mohammad, Allan, Alison L., Feilotter, Harriet, Theis, Ashley, Seymour, Lesley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814290/
https://www.ncbi.nlm.nih.gov/pubmed/29487723
http://dx.doi.org/10.18632/oncotarget.24263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814290/
https://www.ncbi.nlm.nih.gov/pubmed/29487723
http://dx.doi.org/10.18632/oncotarget.24263

Ejemplares similares